• In recent weeks, Halozyme Therapeutics reported record 2025 revenue of about US$1.40 billion, highlighted growing ENHANZE-driven royalties, and outlined progress integrating its Hypercon and Surf Bio acquisitions, while also securing new global collaborations and regulatory approvals for ENHANZE-enabled products.
• Against this backdrop, CEO Helen Torley’s appearance at the TD Cowen Health Care Conference offers investors fresh context on how Halozyme aims to build on its high-margin, royalty-focused model and extended intellectual property runway.
• We’ll explore how Halozyme’s record ENHANZE royalty revenue and recent acquisitions may influence the existing investment narrative around growth and risk.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe its ENHANZE-based, royalty-heavy model can stay attractive even as partners and payers push hard on costs. Record 2025 revenue of about US$1.40 billion and raised 2026 guidance reinforce that the near term catalyst remains continued royalty growth from key drugs, while the biggest risk is still heavy reliance on a handful of blockbuster partners. The TD Cowen talk itself does not materially change those near term drivers or that concentration risk.

Among recent developments, the integration of Hypercon and Surf Bio stands out as most relevant here, because management continues to highlight these assets alongside ENHANZE as part of a broader drug delivery toolkit. As CEO Helen Torley speaks with investors in Boston, the key question is whether these technologies can realistically supplement the ENHANZE franchise enough to soften the long term impact if partner demand, pricing, or competitive drug delivery options shift.

Yet beneath the strong royalty story, there is a concentration risk that investors should be aware of...

Halozyme Therapeutics' narrative projects $2.0 billion revenue and $1.1 billion earnings by 2028. This requires 18.7% yearly revenue growth and an earnings increase of about $0.5 billion from $557.3 million today.

Uncover how Halozyme Therapeutics' forecasts yield a $84.50 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already warning that ENHANZE expansion might lag expectations, even while modeling revenue of about US$2.1 billion and earnings near US$1.1 billion by 2028. Their more cautious view on patent life, pricing pressure, and drug delivery competition could look very different in light of Halozyme’s latest earnings beat and guidance, so it is worth weighing these more pessimistic assumptions alongside the recent news.

Explore 9 other fair value estimates on Halozyme Therapeutics - why the stock might be worth just $84.50!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.